Lynparza improved the time women lived without
disease progression to 22 months in the broad population and to 37 months in
HRD-positive patients as 1st-line maintenance treatment with bevacizumab for
newly-diagnosed advanced ovarian cancer
- リムパーザがアバスチン併用による進行性卵巣がんの一次・維持治療において無増悪期間を全例平均で22か月、HRD陽性例で37か月へと改善した。
